In its work on multiple sclerosis (MS), Biogen has adopted a comprehensive approach that ranges from drug development to the exploration of real-world data and digital markers of disease.
The company will showcase these efforts at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris on October 25–28.
“With more than 25 years of scientific leadership in MS, Biogen’s commitment is unwavering,” Michael Ehlers, executive vice president of research & development at Biogen, said in a press release.
Among its more than 80 presentations at the meeting are updates from its collaboration with Verily and Brigham and Women’s Hospital on using digital sensors that gather data on MS patients between physician visits.
Biogen will also share data on the possibility of using such biomarkers to help neurologists in diagnosing and following MS patients — offering information that could potentially help them in making treatment decisions given the variability of the disease in MS patients.
The company is also involved in a collaboration with 10 MS centers that aims to generate data collected during routine care. The MS PATHS (Partners Advancing Technology and Health Solutions) study includes data from physical examinations, magnetic resonance imaging (MRI) scans, and biological samples.
“With 10 centers now active and strong patient enrollment, our MS PATHS collaboration provides a glimpse into the future of MS care and research,” said Alfred Sandrock, executive vice president and chief medical officer at Biogen.
A third and similar project — the Big Multiple Sclerosis Data (BMSD) Network — is merging data from five MS registries, holding prospective information on nearly 140,000 patients.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?